A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

Name: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Creator: Vivli
Published: 2025-09-17 08:33:55
License: 暂无描述

DataCite Commons2025-09-17 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00011782/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

提供机构：

Vivli

创建时间：

2025-09-16